Physician profile
Luis E Mendez
NPI 1730187287
$7,475.52
in general payments reported to CMS, 2019-2025
25 companies · $799 in 2025
The $799 reported for 2025 was more than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $187 · 2020: $323 · 2021: $1,140 · 2022: $1,111 · 2023: $2,211 · 2024: $1,704 · 2025: $799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,713.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,731.68 | 2022-2025 | Da Vinci Surgical System |
| Abbvie INC. | $1,034.35 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,016.25 | 2020-2025 | Jemperli, Zejula |
| Myriad Genetic Laboratories, INC. | $642.17 | 2021-2024 | Myrisk |
| Biom'Up France Sas | $548.57 | 2021 | |
| Conmed Corporation | $381.26 | 2022-2025 | Airseal |
| Seagen INC. | $334.14 | 2022-2023 | Tivdak |
| Eisai INC. | $269.78 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $261.48 | 2019-2025 | Keytruda, Zerbaxa |
| Ethicon INC. | $249.00 | 2023 | Monarch Platform |
| Pfizer INC. | $247.36 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $205.29 | 2019-2025 | Lynparza |
| Caris Mpi, INC. | $89.25 | 2025 | Mi Cancer Seek |
| Clovis Oncology, INC. | $87.26 | 2019-2022 | |
| Hologic Sales and Service, LLC | $62.62 | 2022-2025 | Aptima, Thinprep 2000 Processor, Myosure Tissue Removal Device |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $53.20 | 2024 | Xt Cdx |
| Coherus Oncology, INC. | $40.99 | 2021-2022 | |
| Allergan, INC. | $38.42 | 2019-2020 | |
| Lilly USA, LLC | $36.51 | 2023 | Jardiance |
| Mayne Pharma Commercial LLC | $29.83 | 2023 | |
| Tesaro, INC. | $25.28 | 2019 | |
| Daiichi Sankyo INC. | $24.66 | 2024 | Enhertu |
| Exeltis, USA INC. | $24.27 | 2025 | Slynd |
| Sumitomo Pharma America, INC. | $24.20 | 2023 | Myfembree |
| Coopersurgical, INC. | $17.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Mendez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.